new_0222_0359|PRLD|0|total_current_assets|cash_on_hand|inventories_net|net_ppe|goodwill_and_intangible|liabilities|total_current_liabilities|total_long_term_liab|total_deposits|book_value_of_equity|retained_earnings|treasury_stock|ev_revenues|ev_earnings|ev_free_cash_flow|ev_assets|ps_ratio|pe_ratio|price_to_book_value|peg_ratio|debt_equity_ratio|dividend_yield|shareholder_yield_ttm|percent_of_shares_outstanding|receivables|payables|capital_stock|return_on_invested_capital|quality_ratio_fractile|momentum_fractile|market_beta_12_month|sustainable_growth_rate|institutional_investor_ownership_percentage|average_shares_outs_diluted|total_employee_number|eps|shares_outstanding|repurchase_of_capital_stock|ordinary_shares_number|payout_ratio|quick_ratio|normalized_eps|stock_buyback|effective_tax_rate|return_on_equity|net_income_ttm|revenues_ttm|dividend_per_share|revenues|gross_profit|sga_expense|pre_tax_income|net_income|interest_income|price|total_return_price|enterprise_value|average_volume_30|one_year_return|price_next_month|price_second_month
new_0222_0359|PRLD|1|Prelude Therapeutics Inc Total Current Assets (Quarterly) (USD)|Prelude Therapeutics Inc Cash and Short Term Investments (Quarterly) (USD)|Prelude Therapeutics Inc Inventories (Quarterly) (USD)|Prelude Therapeutics Inc Net PP&E (Quarterly) (USD)|Prelude Therapeutics Inc Goodwill and Intangibles (Quarterly) (USD)|Prelude Therapeutics Inc Total Liabilities (Quarterly) (USD)|Prelude Therapeutics Inc Total Current Liabilities (Quarterly) (USD)|Prelude Therapeutics Inc Total Long Term Liabilities (Quarterly) (USD)|Prelude Therapeutics Inc Total Deposits (Quarterly) (USD)|Prelude Therapeutics Inc Book Value (Quarterly) (USD)|Prelude Therapeutics Inc Retained Earnings (Quarterly) (USD)|Prelude Therapeutics Inc Treasury Stock (Quarterly) (USD)|Prelude Therapeutics Inc EV to Revenues|Prelude Therapeutics Inc EV to Earnings|Prelude Therapeutics Inc EV to Free Cash Flow|Prelude Therapeutics Inc EV to Assets (Quarterly)|Prelude Therapeutics Inc PS Ratio|Prelude Therapeutics Inc PE Ratio|Prelude Therapeutics Inc Price to Book Value|Prelude Therapeutics Inc PEG Ratio|Prelude Therapeutics Inc Debt to Equity Ratio|Prelude Therapeutics Inc Dividend Yield|Prelude Therapeutics Inc Shareholder Yield (TTM)|Prelude Therapeutics Inc Percent of Shares Outstanding Short|Prelude Therapeutics Inc Total Receivables (Quarterly) (USD)|Prelude Therapeutics Inc Total Payables (Quarterly) (USD)|Prelude Therapeutics Inc Total Capital Stock (Quarterly) (USD)|Prelude Therapeutics Inc Return on Invested Capital|Prelude Therapeutics Inc Quality Ratio Score|Prelude Therapeutics Inc Momentum Score|Prelude Therapeutics Inc Beta (1Y)|Prelude Therapeutics Inc Sustainable Growth Rate (TTM)|Prelude Therapeutics Inc Institutional Investor Ownership Percentage|Prelude Therapeutics Inc Average Diluted Shares Outstanding (Quarterly)|Prelude Therapeutics Inc Total Employees (Annual)|Prelude Therapeutics Inc EPS Diluted (Quarterly) (USD)|Prelude Therapeutics Inc Shares Outstanding|Prelude Therapeutics Inc Repurchase of Capital Stock (Quarterly) (USD)|Prelude Therapeutics Inc Ordinary Shares Number (Quarterly)|Prelude Therapeutics Inc Payout Ratio|Prelude Therapeutics Inc Quick Ratio (Quarterly)|Prelude Therapeutics Inc Normalized Diluted EPS (Quarterly) (USD)|Prelude Therapeutics Inc Stock Buybacks (Quarterly) (USD)|Prelude Therapeutics Inc Effective Tax Rate (TTM)|Prelude Therapeutics Inc Return on Equity|Prelude Therapeutics Inc Net Income (TTM) (USD)|Prelude Therapeutics Inc Revenue (TTM) (USD)|Prelude Therapeutics Inc Dividend Per Share (Quarterly) (USD)|Prelude Therapeutics Inc Revenue (Quarterly) (USD)|Prelude Therapeutics Inc Gross Profit (Quarterly) (USD)|Prelude Therapeutics Inc SG&A Expense (Quarterly) (USD)|Prelude Therapeutics Inc Pre-Tax Income (Quarterly) (USD)|Prelude Therapeutics Inc Net Income (Quarterly) (USD)|Prelude Therapeutics Inc Net Interest Income (Quarterly) (USD)|Prelude Therapeutics Inc Price (USD)|Prelude Therapeutics Inc Total Return Price (USD)|Prelude Therapeutics Inc Enterprise Value (USD)|Prelude Therapeutics Inc 30-Day Average Daily Volume|Prelude Therapeutics Inc 1 Year Price Returns (Daily)||
new_0222_0359|PRLD|2|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|percent_USD_metric|percent_USD_metric|percent_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|percent_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_beta|percent_USD_metric|percent_USD_metric|mil_figure_USD_metric|figure_whole_USD_metric|figure_money_USD_per_share_metric|mil_figure_USD_metric|mil_figure_money_USD_metric|mil_figure_USD_metric|percent_USD_metric|figure_USD_metric|figure_money_USD_per_share_metric|mil_figure_money_USD_metric|percent_USD_metric|percent_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|figure_money_USD_per_share_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|figure_money_USD_price|figure_money_USD_price|mil_figure_money_USD_metric|figure_USD_metric|percent_USD_metric||
new_0222_0359|PRLD|4|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|daily|quarterly|quarterly|quarterly|daily|quarterly|quarterly|daily|quarterly|monthly|quarterly|quarterly|quarterly|quarterly|quarterly|monthly|monthly|quarterly|quarterly|quarterly|quarterly|quarterly|monthly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|daily|daily|daily|daily|daily||
new_0222_0359|PRLD|5|106.5|106.5|0|106.5|0|106.5|106.5|106.5|0|106.5|106.5|0|0|0|1.44912280702|0|0|0|1.44571428571|0|0|1.44886363636|0|15.25|0|106.5|106.5|0|0|30.6666666667|30.75|0|0|91.375|91.4|91.375|25.5625|0|106.5|0|0|91.375|91.3333333333|0|0|91.4|0|0|0|0|91.375|91.375|91.375|0|1.44759206799|1.44759206799|1.44886363636|1.4520123839|1.43||
new_0222_0359|PRLD|6|6|6|0|6|0|6|6|6|0|6|6|0|0|0|285|0|0|0|350|0|0|352|0|32|0|6|6|0|0|3|4|0|0|8|5|8|16|0|6|0|0|8|6|0|0|5|0|0|0|0|8|8|8|0|353|353|352|323|100||
new_0222_0359|PRLD|7|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|daily|quarterly|daily|quarterly|daily|daily|daily|daily|quarterly|daily|quarterly|daily|quarterly|quarterly|quarterly|quarterly|quarterly|monthly|monthly|quarterly|monthly|quarterly|yearly|quarterly|daily|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|market_daily|market_daily|daily|market_daily|market_daily||
new_0222_0359|PRLD|201909||||||||||||||||||||||||||||||||||32.4018||-0.2078||||||-0.2078|||||||||1.394|-6.734|-6.734||||||||
new_0222_0359|PRLD|201912|20.224|18.879||1.647||71.283|4.835|66.448||-49.412|-50.497|||||||||||||||1.974|0|||||||32.4018||-0.3098|||42.4546|||-0.3098|||||||||1.246|-10.039|-10.039||||||||
new_0222_0359|PRLD|202003||||||||||||||||||||||||||||||||||32.4018||-0.2935||||||-0.2935|0||||||||1.201|-9.511|-9.511||||||||
new_0222_0359|PRLD|202006|30.697|29.716||1.575||102.058|5.639|96.419||-69.311|-71.416|||||||||||||||3.471|0|||||||42.4546|51|-0.2687|||42.4546|||-0.2687|0|||-37.692|||||1.66|-11.408|-11.408||||||||
new_0222_0359|PRLD|202009|238.061|234.792||1.62||11.374|11.359|0.015||228.307|-88.176||||||||5.7676|||0||0.0132||5.074|0.004||||||85.9318|3.1945|55|-5.25|43.7034||43.7034|||-5.25|-167.929|||-47.718|||||2.851|-16.76|-16.76||19|19|1082.5945|116194.5333||34.78|47.67
new_0222_0359|PRLD|202012|220.809|218.309||2.48||11.407|11.375|0.032||212.183|-107.426||||-62.1572||||14.4391|||0||2.8086||3.92|0.004|||||||43.7057|68|-0.4404|43.7057||43.7057|||-0.4404|1.299|||-56.929|||||4.874|-19.25|-19.25||83.81|83.81|3427.99|194045.8667||69.93|66.72
new_0222_0359|PRLD|202103|365.018|362.99||4.813||13.264|12.424|0.84||356.567|-128.726||||-30.8656||||5.686|||0||3.6742||4.842|0.005|||||||45.122|105|-0.47|46.7909||46.7909|||-0.47|-161.424|||-68.718|||||5.497|-21.3|-21.3||43.33|43.33|1664.4597|200349.4333||39.48|33
new_0222_0359|PRLD|202106|344.575|343.119||5.006||15.22|14.677|0.543||334.361|-155.591||||-15.3749||||4.0277|||0||7.231||6.844|0.005|||||||46.0571|100|-0.58|47.0387||47.0387|||-0.58|0|||-84.175|||||5.513|-26.865|-26.865||28.63|28.63|1003.599|224939.7||34.78|34.5
new_0222_0359|PRLD|202109|325.897|320.865||5.32||19.975|19.663|0.312||311.242|-186.278||||-15.3787||||4.3522|||0||9.4094||11.062|0.005|||4|2.5212|||46.3308|113|-0.66|47.1918||47.1918|||-0.66|0|||-98.102|||||8.115|-30.687|-30.687||30.9|30.9|1112.0702|330443.5333|3.7172|17.31|14.31
new_0222_0359|PRLD|202112||291.233||||19.201|||||||||-3.5581||||1.8826|||0||10.8962||||||1|-1.1063|||||-0.71|47.6023|||||||||-111.694|||||7.832||-32.842||12.41|12.41|265.0781|467703.0333|-82.5996|8.99|9.89
new_0222_0359|PRLD|202203||266.189||||18.859|||||||||||||1.1596|||||||||||||||||-0.63|47.6954|||||||||-119.859|||||7.467||-29.465||6.96|6.96|40.2836|197595.1667||4.92|4.42
new_0222_0359|PRLD|202206||246.305||||18.211|||||||||||||0.9437|||||||||||||||||-0.58|47.7713|||||||||-120.368|||||8.151||-27.374||5.18|5.18|-19.1258|230408.9||5.89|7.2
new_0222_0359|PRLD|202209||224.043||||24.92|||||||||||||1.3168|||||||||||||||||-0.63|47.8468|||||||||-119.639|||||7.517||-29.958||6.63|6.63|70.8298|74634.5||7.18|6.67
new_0222_0359|PRLD|202212||201.728||||25.063|||||||||||||1.1205|||||||||||||||||-0.6|47.899|||||||||-115.438|||||7.516||-28.641||5.09|5.09|19.5634|93063.7333||7.34|5.6
new_0222_0359|PRLD|202303||172.255||||23.023|||||||||||||1.569|||||||||||||||||-0.58|47.9163|||||||||-113.691|||||7.281||-27.718||6.4|6.4|104.9146|65470||6.02|5.58
new_0222_0359|PRLD|202306||254.989||||18.551|||||||||||||1.3884|||||||||||||||||-0.54|54.8087||||||-110.691|||-116.748|||||7.432||-30.431||4.64|4.64|71.1209|170794.4667||4.12|3.83
new_0222_0359|PRLD|202309||230.506||||20.254|||||||||||||0.6421|||||||||||||||||-0.45|54.8157||||||-0.104|||-117.398|||||7.124||-30.608||3.07|3.07|-86.7263|136170.9||2.07|3.36
new_0222_0359|PRLD|202312||232.935||||40.575|||||||||||||0.9274|||||||||||||||||-0.47|54.9143||||||-24.936|||-121.832|||||7.047||-33.075||4.03|4.03|-1.3103|220841.0667||3.28|4.17
new_0222_0359|PRLD|202403||201.924||||36.372|||||||||||||1.1049|||||||||||||||||-0.42|54.9218|||||||||-125.545|||||6.934||-31.431||4.77|4.77|20.249|79535.3333||3.87|3.32
new_0222_0359|PRLD|202406||179.844||||42.015|||||||||||||0.9618|||||||||||||||||-0.46|55.0085|||||||||-129.854|||||7.655||-34.74||3.69|3.69|6.2592|50442.7||5.79|5.2
new_0222_0359|PRLD|202409||153.626||||40.789|||||||||||||0.64|||||||||||||||||-0.43|55.0283|||||||||-131.517|||3||7.919||-32.271||2.12|2.12|-58.7901|402791.7333||1.52|1.05
new_0222_0359|PRLD|202412||133.614||||44.056|||||||||||||0.4714|||||||||||||||||-0.38|55.1491|||||||||-127.173|||4||6.211||-28.731||1.34|1.34|-63.2989|600700.5333||1.1|0.759
new_0222_0359|PRLD|202503||99.074||||38.082|||||||||||||0.2683|||||||||||||||||-0.42|56.4545|||||||||-127.827|||||5.79||-32.085||0.7997|0.7997|-95.2595|197699.9333||0.9009|0.7996
new_0222_0359|PRLD|202506|||||||||||||||||||0.4678||||||||||||||||||||||||||||||||||||0.8761|0.8761|-49.609|154664.3667||0.7939|